Juneflecad Laboratorios Liconsa, S.A.

Flecainide, the active ingredient in Juneflecad Laboratorios Liconsa, S.A., is a Class Ic antiarrhythmic presented as an oral formulation for oral use. It is employed to treat ventricular and supraventricular arrhythmias, including atrial fibrillation, in adult patients. The drug works by selectively blocking fast inward sodium channels, thereby slowing cardiac conduction and extending the refractory period.

GNH USA supplies Juneflecad Laboratorios Liconsa, S.A. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Flecainide is used to manage cardiac rhythm disorders affecting the ventricles and atria.

- Ventricular arrhythmias: restores normal rhythm by suppressing premature ventricular beats. - Supraventricular arrhythmias: controls rapid atrial rhythms such as atrial flutter. - Atrial fibrillation: helps maintain sinus rhythm or control ventricular rate in AF patients.

Flecanyde may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Visual disturbances: blurred vision or photopsia. - Nausea: mild gastrointestinal upset. - Headache: intermittent cranial pain. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Proarrhythmia: new or worsening arrhythmias, including ventricular tachycardia. - Heart block: atrioventricular conduction delay or complete block. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, pruritus, or angioedema. - Hepatotoxicity: elevated liver enzymes or liver injury.

When prescribing Flecainide, clinicians should observe several safety considerations.

- Cardiac assessment: perform baseline ECG and evaluate for structural heart disease before initiation. - Renal function: adjust monitoring in patients with impaired renal clearance. - Concomitant drugs: avoid use with other Class I antiarrhythmics or drugs that prolong QT interval. - Pregnancy and lactation: use only if potential benefit outweighs risk; limited data available. - Patient education: advise on recognizing signs of arrhythmia recurrence or dizziness. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Flecainide interacts with several medicines that can alter its plasma levels or cardiac effects.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., quinidine, propafenone): may markedly increase Flecainide concentrations. - Other Class I antiarrhythmics (e.g., lidocaine, procainamide): additive proarrhythmic risk. - Drugs that significantly prolong QT interval (e.g., sotalol, certain macrolide antibiotics): heightened arrhythmia potential.

Moderate Interactions (Monitor Closely): - Digoxin: may require dose adjustment due to additive effects on conduction. - Beta‑blockers: combined use can enhance bradycardia or AV block. - Calcium channel blockers (verapamil, diltiazem): may increase Flecainide levels via metabolic pathways.